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ABSTRACT
Clostridium diﬃcile ribotype (RT) 017 is an important toxigenic C. diﬃcile RT which, due to a deletion in the repetitive region
of the tcdA gene, only produces functional toxin B. Strains belonging to this RT were initially dismissed as nonpathogenic
and circulated largely undetected for almost two decades until they rose to prominence following a series of outbreaks in
the early 2000s. Despite lacking a functional toxin A, C. diﬃcile RT 017 strains have been shown subsequently to be
capable of causing disease as severe as that caused by strains producing both toxins A and B. While C. diﬃcile RT 017
strains can be found in almost every continent today, epidemiological studies suggest that the RT is endemic in Asia
and that the global spread of this MLST clade 4 lineage member is a relatively recent event. C. diﬃcile RT 017
transmission appears to be mostly from human to human with only a handful of reports of isolations from animals. An
important feature of C. diﬃcile RT 017 strains is their resistance to several antimicrobials and this has been
documented as a possible factor driving multiple outbreaks in diﬀerent parts of the world. This review summarizes
what is currently known regarding the emergence and evolution of strains belonging to C. diﬃcile RT 017 as well as
features that have allowed it to become an RT of global importance.
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Introduction
Clostridium diﬃcile is an important cause of antimicro-
bial-associated diarrhoea (AAD) in both humans and
animals [1]. In humans, the disease can progress
from watery diarrhoea to life-threatening pseudomem-
branous colitis (PMC) and toxic megacolon [2].
C. diﬃcile infection (CDI) is a toxin-mediated disease
and major virulence factors include toxin A (TcdA,
308 kDa) and toxin B (TcdB, 270 kDa) [3]. An
additional binary toxin (C. diﬃcile transferase, CDT)
is produced by some strains only. CDT-producing
strains of C. diﬃcile account for an increasing pro-
portion of human infections in some parts of the
world (currently ca. 20% of CDI cases in non-outbreak
situations) but are common in animals [4,5]. C. diﬃcile
can be classiﬁed into diﬀerent PCR ribotypes (RTs)
using banding patterns of the ampliﬁed intergenic
spacer region between the 16S and 23S rRNA genes
[6]. Currently, over 600 RTs exist in the United King-
dom-based C. diﬃcile Ribotyping Network (CDRN)
database [7].
C. diﬃcile RT 017 ranks among the most successful
RTs of C. diﬃcile. A toxigenic strain that produces only
TcdB [8], RT 017 causes disease as severe as other toxi-
genic strains [9–12]. Although C. diﬃcile RT 017
appears to have originated in Asia, it has spread glob-
ally and been responsible for multiple outbreaks
around the world [13–23]. Few studies have been con-
ducted to identify factors that may have contributed to
the success of RT 017 [16,18]. This review summarizes
what is known about C. diﬃcile RT 017 regarding its
history, characteristics, evolution, emergence and glo-
bal dissemination.
Brief history of C. diﬃcile infection and the
emergence of C. diﬃcile RT 017
C. diﬃcile (then named Bacillus diﬃcilis) was ﬁrst
described in 1935 as part of neonatal gut ﬂora. It pro-
duced a potent cytotoxin that caused tissue oedema,
convolution and death when injected subcutaneously
into guinea pigs and rabbits [24]. However, there
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were no reports of human gastrointestinal infections
associated with C. diﬃcile until 1978 when, after a
period of intense trans-Atlantic competition between
researchers, C. diﬃcile was identiﬁed in faecal speci-
mens from patients with PMC [25].
Not all strains of C. diﬃcile produce toxins and
cause disease. Initially, it was thought that all toxigenic
strains of C. diﬃcile produced both major toxins [26].
For two decades after the association between
C. diﬃcile and PMC was shown, it was believed that
TcdA was required to cause initial damage to the intes-
tinal mucosa before TcdB could exert its potent cyto-
toxic eﬀect [27], and the signiﬁcance of TcdA-
negative, TcdB-positive (A-B+) stains was not apparent
[17]. To further support this belief, the ﬁrst few strains
of C. diﬃcile isolated with an A-B+ phenotype were
associated only with asymptomatic carriage [28].
During this same period, there was a move away
from using the faecal TcdB cytotoxicity assay and/or
culture of C. diﬃcile for diagnostic purposes due to
the time and expense involved in maintaining and
using cell lines, and the long turnaround time of cul-
ture. Concomitantly, there was an emphasis on devel-
oping rapid immunoassays for the detection of TcdA
[29]. TcdA was chosen because of the continued mista-
ken belief that C. diﬃcile produced either both TcdA
and TcdB, or no toxins, because it was easier to manu-
facture antibodies against TcdA, and because detection
of TcdA had greater sensitivity compared to detection
of TcdB [30]. These tools made the detection of
C. diﬃcile easier, but with far less overall sensitivity,
and further obscured the signiﬁcance of A-B+
C. diﬃcile strains.
The importance of A-B+ strains of C. diﬃcile was
ﬁnally appreciated at the end of the twentieth century
when 16 patients in a Canadian tertiary-care hospital
developed PMC with an A-B+ strain. Stool samples
from these patients tested negative for C. diﬃcile
TcdA but were later shown via a cytotoxin assay to
contain C. diﬃcile that produced a functional TcdB
only [17]. Similar ﬁndings were published from other
countries [13,16] and further studies conﬁrmed these
strains as A-B+ C. diﬃcile RT 017 [8]. At the same
time, a study reported that not only could TcdB exert
its cytotoxic eﬀect in the absence of TcdA, but also
that human intestinal mucosa was around 10 times
more sensitive to TcdB than TcdA [31]. This was the
ﬁrst time that the clinical signiﬁcance of A-B+
C. diﬃcile became evident [32]. Over the last 20
years, C. diﬃcile RT 017 has been isolated from many
parts of the world, however, it is likely that C. diﬃcile
RT 017 originated from a single geographical region
and its global dispersal has been a relatively recent
event [33].
Characteristics of C. diﬃcile RT 017
Epidemiological typing of C. diﬃcile RT 017
Currently, PCR ribotyping is a method of typing
C. diﬃcile that is widely used in many parts of the
world due to its relative simplicity and high discrimina-
tory power [34]. However, ribotyping requires com-
parison of banding patterns with those of standard
strains present in a library of patterns that was estab-
lished in 1999 [6]. Thus, reports of C. diﬃcile before
or around that time classiﬁed C. diﬃcile by various
other methods [17,35]. Table 1 summarizes these
diﬀerent methods used when referring to C. diﬃcile
RT 017. Early ribotyping studies in Japan used their
own nomenclature and assigned “fr” to RT 017 [36].
Before genotype-based methods, C. diﬃcile was
classiﬁed using phenotypic methods that, in general,
had poor reproducibility, low typeability, and lacked
suﬃcient discriminatory power to be applied to epide-
miological studies [42]. However, serogrouping was
widely used early and showed a good correlation with
toxigenicity [43]. Serogrouping classiﬁed C. diﬃcile
RT 017 as either serogroup F or X [37].
Many genotypic methods, including ribotyping, use
unique banding patterns of diﬀerent PCR products to
classify C. diﬃcile strains. Toxinotyping detects diﬀer-
ences in the Pathogenicity Locus (PaLoc) and classiﬁes
C. diﬃcile RT 017 as toxinotype VIII [38]. Pulsed-ﬁeld
gel electrophoresis is more commonly used in North
America and classiﬁes C. diﬃcile RT 017 as North
American pulsed-ﬁeld gel electrophoresis type 9
(NAP 9) [39]. Restriction endonuclease analysis
(REA) typing has greater discriminatory power than
ribotyping and divides C. diﬃcile RT 017 into several
REA types which are grouped as REA groups CF and
CG [37].
Multi-locus sequence typing (MLST) is another gen-
otype-based method involving 7 housekeeping genes.
However, it is not based on banding patterns but rather
the unique sequences of these genes and thus has been
used mainly in evolutionary studies. This method clas-
siﬁes C. diﬃcile RT 017 as sequence type (ST) 37
belonging to evolutionary clade 4 [40]. MLST has
good discriminatory power, however, it is relatively
Table 1. C. diﬃcile RT 017 categorized by other classiﬁcation
methods.
Classiﬁcation Method Type(s) Reference
Serogrouping F, X [37]
Toxinotyping VIII [38]
NAP typing NAP 9 [39]
REA grouping CF1, CF2, CF3, CF4, CF5,CF6,
CG1, CG3
[37]




Note: NAP; North American pulsed-ﬁeld gel electrophoresis, REA; restriction
endonuclease analysis, MLST; multilocus sequence typing, ST; sequence
type, * a study in Thailand [41] performed MLST using a diﬀerent data-
base and classiﬁed RT 017 as ST 45.
Emerging Microbes & Infections 797
more complicated to perform [34]. The advent of next-
generation sequencing makes in silicoMLST now more
accessible [44].
A recent study in China reported that RT 017 can
also be identiﬁed using matrix-assisted laser desorption
ionization time-of-ﬂight mass spectrometry (MALDI-
TOF MS) with high sensitivity and speciﬁcity [45].
However, this study did not include other C. diﬃcile
strains from clade 4 and another Chinese study
suggested that diﬀerent clade 4 strains may not be dis-
tinguishable by this method [46].
C. diﬃcile RT 017 toxin
C. diﬃcile RT 017 is classiﬁed as A-B+ C. diﬃcile as it
produces only a functional TcdB [8]. Its TcdB also
gives a diﬀerent cytopathic eﬀect (CPE) in cell cyto-
toxin assays using various cell lines compared to
other strains that is often referred to as a variant CPE
[16,47]. Studies on the tcdA gene of C. diﬃcile RT
017 revealed a 1.8 kb deletion in the repeating region
(3′ end) (Figure 1) and a point mutation in the
5′ end which results in a premature stop codon
[49,50]. The 1.8 kb deletion corresponds to a deletion
of the carboxy repetitive oligopeptide (CROP) region
of TcdA, which is the recognition site of many TcdA
enzyme immunoassays (EIAs), making the toxin
undetectable by these EIAs [47]. The nonsense
mutation at 5′ end corresponds with a loss of catalytic
action of the TcdA, thus making the toxin non-func-
tional [47,49].
Notably, despite lacking a functional TcdA, most of
the tcdA gene in C. diﬃcile RT 017 remains intact and
can be detected by PCR if primers speciﬁc to the non-
repeating region of the tcdA gene are used. In such
cases, C. diﬃcile RT 017 could be incorrectly detected
as both tcdA- and tcdB-positive C. diﬃcile [51].
While these primers are eﬃcient for detection of toxi-
genic strains in clinical practice, the results may appear
confusing in an epidemiological study. An additional
primer set is needed to identify the deletion in the
repeating region of tcdA gene and diﬀerentiate
C. diﬃcile RT 017 from true A+B+ C. diﬃcile strains
[28,52].
Interestingly, the TcdB of RT 017 (TcdB-F) is diﬀer-
ent from the TcdB commonly found in most C. diﬃcile
strains. TcdB-F behaves as a “functional hybrid,” com-
bining characteristics of both TcdB and the Clostridium
sordellii lethal toxin, TclS. While TcdB-F binds to the
same cellular receptors as TcdB, the two proteins dis-
play diﬀerences in their target speciﬁcity, with TcdB
primarily glucosylating Rho, Rac and Cdc42 targets,
and TcdB-F glucosylating Rac and Ras targets
(Figure 2) [48]. The diﬀerence in cellular targets is
thought to be responsible for the diﬀerent CPE
observed for the two toxins [50].
Infection due to C. diﬃcile RT 017
Despite producing toxin B only, several studies suggest
that C. diﬃcile RT 017 causes clinical disease that is
indistinguishable from that caused by other
C. diﬃcile RTs [9,12]. In addition, C. diﬃcile RT 017
causes disease as severe as that caused by “hyperviru-
lent” C. diﬃcile RT 027 [10]. In an outbreak setting,
mortality due to C. diﬃcile RT 017 can be as high as
37.5% [47], but this high mortality rate may have
been due to the exclusion of mild cases. There have
been no clinical studies of C. diﬃcile RT 017 infection
in South East Asia, where there is a high prevalence of
RT 017 [41,53,54]. Given that CDI in this region was,
in general, associated with low mortality and recur-
rence [55], it will be interesting to see whether the
less severe CDI in this region is speciﬁcally associated
with C. diﬃcile RT 017 or if there are other unknown
protective factors in the population or region, such as
a high prevalence of carriage of non-toxigenic strains,
which may occupy the same niche and competitively
exclude toxigenic strains from the gut [53,56,57].
Evolution and transmission of C. diﬃcile RT
017
Based on MLST and Bayesian evolutionary model
analysis (Figure 3), C. diﬃcile has evolved into at
least ﬁve clades and three cryptic clades. This clade
divergence occurred more than a million years ago
[34]. C. diﬃcile RT 017 (ST 37; red arrowhead in
Figure 3) is a member of C. diﬃcile clade 4 along
with many non-toxigenic, and some similar toxigenic,
strains [46,58–61]. Despite limited data, it is clear
that both A-B+CDT- and non-toxigenic strains of
C. diﬃcile (orange and green, respectively, in Figure 3)
are equally distributed throughout clade 4, indicating
Figure 1. Comparative analysis of the PaLoc from C. diﬃcile RT
017 and A + B + C. diﬃcile strains. Arrows indicate open read-
ing frames (ORFs) and the direction of transcription. The diﬀer-
ent enzymatic domain of the tcdB gene is responsible for the
diﬀerent CPE [48]. The nonsense mutation near the 5′ terminal
of the tcdA gene is responsible for the loss of function of TcdA
[49]. The 1.8 kb deletion near the 3′ terminal of the tcdA gene
makes TcdA undetectable by many toxin EIAs [47].
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that the clade 4 ancestor could either be a toxigenic (A-
B+CDT-) or non-toxigenic strain. A recent study
analyzed time-scaled core-genome phylogenies and
suggested that the clade 4 ancestor was a non-
toxigenic strain of C. diﬃcile, and that acquisition of
the PaLoc in C. diﬃcile RT 017 occurred around 500
years ago [59].
To date, the genomes of twoC. diﬃcileRT017 strains
(CF5, isolated in Belgium in 1995, and M68, isolated in
Ireland in 2006) have been completely sequenced, pro-
viding important reference chromosomes for whole
genome sequencing (WGS) studies of this lineage
[62]. Figure 4 shows the genome of C. diﬃcile strain
M68. Using WGS, Cairns et al. showed that 23 of 24
of C. diﬃcile RT 017 strains from one hospital were clo-
sely related and formed a single cluster. The only unre-
latedC. diﬃcileRT017 strainwas isolated fromapatient
with community-acquired CDI and this belonged to a
cluster from outer London hospitals. These ﬁndings
suggested thatC. diﬃcileRT017wasmostly transmitted
betweenpatients in the sameward and betweenwards in
the samehospital. The study further found that environ-
mental contamination with clinical isolates was possible
and that RT 017 could withstand decontamination with
hydrogen peroxide vapour [22].
Another WGS study of 277 diﬀerent C. diﬃcile RT
017 strains isolated from around the world, including
24 from animals (cattle, dogs, and horses) showed
that C. diﬃcile RT 017 could be transmitted between
humans and animals, and also reported that deletions
and insertions found in RT 017 genomes were distrib-
uted throughout all geographical areas [33]. The
ﬁnding of little genetic diversity implies that
C. diﬃcile RT 017 originated in a single geographical
area and that global spread occurred relatively recently,
however, it remained unclear where that single geo-
graphical area was. Cairns et al. [33] concluded that
C. diﬃcile RT 017 originated in North America and
then spread to Europe, Asia and other parts of the
world [33]. This conclusion contradicts many epide-
miological studies (see below) that, taken collectively,
suggest that the origin of C. diﬃcile RT 017 is in Asia.
The Cairns et al. study included only a limited number
of historic C. diﬃcile RT 017 isolates from Asia (2
strains from Korea and 1 strain from Japan, all isolated
in 1995) and a greater number of C. diﬃcile RT 017
strains from North America (9 strains from the United
States isolated from 1990 to 1996).
Global dissemination of C. diﬃcile RT 017
Despite producing only one toxin, C. diﬃcile RT 017
has successfully spread throughout the world with evi-
dence of human infection in North America
[17,39,47,63–66], Europe [8,13,16,20,22,23,67,68],
Asia [9,14,15,19,69–76], South America [18], Africa
[77], and Australia [78–81]. Figure 5 summarizes
chronologically the major events surrounding the
detection of C. diﬃcile RT 017 from around the
world, comparing studies of prevalence during out-
breaks to studies in non-outbreak settings.
Reports on C. diﬃcile RT 017 infection started in the
late 1990s with a series of outbreaks in Poland [13],
Japan [14,15], the Netherlands [16], Canada [17], and
Argentina [18]. During the early 2000s, there were out-
breaks of so-called “hypervirulent” C. diﬃcile RT 027
in Europe and North America [82], and the number
of RT 017 reports appeared to subside
Figure 2. The cytotoxic eﬀect of TcdB and TcdB-F on VERO cells. VERO cells were treated with the supernatant of 72-hour-old cul-
tures of C. diﬃcile strain 2149 (RT 014/020 which produces TcdB), C. diﬃcile strain 1470 (RT 017 which produce TcdB-F), and
C. diﬃcile ATCC 700057 (RT 038 which is non-toxigenic) and incubated at 37°C for 24 hours before inspection under a light micro-
scope. TcdB glycosylates Rho, Rac, and Cdc42 targets resulting in arborization of cells while TcdB-F glycosylates Rac and Ras targets
resulting in rounding of cells without arborization.
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[39,63,67,68,83–85]. Still, there were further outbreaks
of RT 017 infection in Ireland and Taiwan during 2003
and 2004 [19–21], and in Sweden in 2008 [23]. The
most recent documented outbreak of RT 017 infection
started in 2009 in England and persisted for at least 3
years [22].
Among these C. diﬃcile RT 017 outbreaks, clinical
characteristics of the patients were described only in
reports from the outbreak in Canada, with 18.8% (3/
16) of cases having PMC, 31.3% (5/16) of cases being
recurrent and a 37.5% (6/16) mortality rate [17,47].
Outbreaks of C. diﬃcile RT 017 infection have been
Figure 3. Sequence type diversity in evolutionary clade 4. Maximum-likelihood MLST phylogeny. Sequences were aligned using
MUSCLE and tree was generated in MEGA7 with evolutionary distances calculated using the Tajima-Nei model. The scale shows
the number of nucleotide substitution per site, based on concatenated MLST allele sequences (7 loci, 3501 bp). The tree is mid-
point rooted and supported by 500 bootstrap replicates (only values >50 are shown). For global phylogenetic context, well-charac-
terised representatives of MLST clade 1 (ST 54), 2 (ST 1), 3 (ST 22), 5 (ST 11), C1 (ST 181), C2 (ST 200), and C3 (ST 204) are also shown
(*). Branches for clade 4 are shown in blue. Known toxin proﬁles of clade 4 strains are indicated by orange (A-B+CDT-) and green (A-
B-CDT-) colour. RT 017 (ST 37) is indicated with a red arrowhead.
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linked to the use of clindamycin [16] and ﬂuoroquino-
lones [21]. In both outbreaks, discontinuation of the
oﬀending agent resulted in a rapid decline in the num-
ber of CDI cases due to C. diﬃcile RT 017 [16,21]. This
suggests that these outbreaks were associated with the
use of speciﬁc antimicrobials and that antimicrobial
stewardship helped to control spread.
Besides many outbreaks, there have also been non-
outbreak reports of C. diﬃcile RT 017 throughout the
world. The majority of these reports with high preva-
lence ﬁgures were from Asia, while reports from non-
Asian countries mostly recorded low prevalence
ﬁgures. Data summarizing the prevalence of C. diﬃcile
RT 017 in Asia and non-Asian countries can be found
in Tables S1 and S2 in the supplementary document.
C. diﬃcile RT 017 in Asia
It is likely that C. diﬃcile RT 017 is endemic in Asia and
has been resident in this region for a long time, for
three diﬀerent reasons. First, in contrast to non-Asian
countries, RT 017 appeared mainly in non-outbreak-
related prevalence studies [41,53,54,69,71–75,86–88].
Second, there have been reports of A-B+CDT-
C. diﬃcile RTs in the region other than C. diﬃcile RT
017 with similar deletions in the tcdA gene, some of
which have also been classiﬁed in MLST clade 4
[46,58,60,61,71,89]. Third, the earliest Asian isolates
of RT 017 in humans can be dated back to 1993 in
Indonesia, where ﬁve strains of RT 017 were isolated
from healthy infants [15]. The high prevalence and
diversity of A-B+CDT- C. diﬃcile in Asia and the evi-
dence of old C. diﬃcile RT 017 isolates suggest that the
origin of this RT is in Asia. While Asia is a very large
continent, current information suggests that
C. diﬃcile RT 017 is endemic in at least two diﬀerent
regions of the continent: parts of East Asia, and
South East Asia [90].
East Asia
East Asia can be geographically divided into Japan and
the mainland section which consists of China (includ-
ing Hong Kong), North and South Korea, and the
island of Taiwan. The prevalence of diﬀerent
C. diﬃcile RTs in these two areas varies with RT 017
being a predominant strain only in the mainland sec-
tion plus Taiwan [9,19,69–75]. Historically, RT 017
has been responsible for ca. 15–40% of patients with
CDI in South Korea [9,69–71], China [72–74], and Tai-
wan [19,75]. In Taiwan, there was an increase in the
prevalence of C. diﬃcile RT 017 that resembled an out-
break in 2004 (73.3%; 11/15), but the prevalence even-
tually decreased to an endemic rate of 23.9% (11/46) in
2007 [19].
In contrast to these reports, Japan saw an outbreak
of C. diﬃcile RT 017 infection in 1996 [14,15], perhaps
coincidentally, around the same time as RT 017 out-
breaks in Poland, the Netherlands and Canada
[13,16,17,67]. However, there have been no major
reports of C. diﬃcile RT 017 infection in Japan since.
Interestingly, in 2001, there was an outbreak of CDI
caused by an A-B+ strain of C. diﬃcile with an RT pat-
tern resembled C. diﬃcile RT 017 [91]. This strain was
later identiﬁed as the novel C. diﬃcile RT 369, a strain
that is closely related to C. diﬃcile RT 017 [36], and
that was recently identiﬁed in China as ST 81, a single
loci variant of ST 37 [92]. To date, RT 369 remains
among the most common toxigenic strains isolated in
Japan while only a small number of C. diﬃcile strains
belonging to RT 017 have been detected [93].
South East Asia
Most epidemiological studies in South East Asia have
been conducted in Thailand [41,53,89] with additional
reports from Indonesia [54], Laos [86], Malaysia
[56,87] and Singapore [88]. Although the information
is limited, based on these publications, and some
Figure 4. A. Circular representation of the genome of
C. diﬃcile strain M68 (RT 017, ST 37, GenBank accession num-
ber NC017175.1). From outside to inside, the concentric circles
represent (1) and (2) all coding sequences (CDS) transcribed in
clockwise and counter-clockwise, (3) all rRNA, (4) all tRNA, (5)
transposons (Tn6194 containing ermB gene represented in
red and Tn6190 containing tetM gene represented in purple)
and prophages (counterclockwise from top; ΦCDHM19
[58,163 bp, GC% = 31.34%], ΦCDHM13 [39,325 bp, GC% =
29.34%], and ΦMMP01 [55,106 bp, GC% = 28.87%]), and (6)
GC content. B. Key characteristics of the genome.
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publications from Thailand that detected a high preva-
lence of A-B+ C. diﬃcile [94–96], it is likely that RT 017
is endemic throughout this region.
Despite isolating C. diﬃcile RT 017 strains as early
as 1993 [15], there were no epidemiological studies in
the region until 2006 [41]. All studies thereafter
reported similar results. In Thailand, three studies
conﬁrmed that C. diﬃcile RT 017 ranks among the
most common toxigenic strains present (ca. 30.8% –
41.5%) [41,53,89]. In Indonesia, C. diﬃcile RT 017
was the most prevalent RT isolated from patients
[54]. C. diﬃcile RT 017 has been isolated in Laos
[86], although only ﬁve patients were included in this
report. The most recent report from South East Asia
came from Malaysia where the prevalence of
C. diﬃcile RT 017 was 20.0% [56]. In contrast to
other South East Asian countries, a study in Singapore
reported a low prevalence of RT 017 of 4.9% (3/61),
and an RT distribution more like European countries.
The comment was made that this possibly reﬂected
the international population of Singapore, both resi-
dent and passing through [88].
C. diﬃcile RT 017 in non-Asian countries
Outside Asia, C. diﬃcile RT 017 is mostly associated
with outbreaks. The ﬁrst group of outbreaks was
reported from 1995 to 1998 in Poland [13], the Nether-
lands [16] and Canada [17]. These outbreaks occurred
during the same time-frame as the Japanese outbreak
[14,15]. Since 2000, there have been four outbreaks of
C. diﬃcile RT 017 infection outside Asia [18,20–23].
Even though there have been non-outbreak reports of
RT 017 in some parts of the world, the prevalence is
low in most areas (≤10%) when compared to Asia
[8,13,16,20,22,39,63,67,68,78–81].
North America
After 2002, C. diﬃcile RT 017 was rapidly oversha-
dowed by the emergence of the “hyper-virulent”
C. diﬃcile RT 027 in this region [82]. The prevalence
of C. diﬃcile RT 017 in Canada decreased from 5.4%
(58/1,080) during 2004–2006 [63] to 1.3% (17/1,310)
during 2013–2015 [83]. The prevalence of C. diﬃcile
RT 017 in the United States was ca. 2–3% during
2010–2012 [64–66]. In 2011, the overall prevalence of
RT 017 in North America was reported at 4.3% (15/
350) of toxigenic strains [39].
Europe
Apart from obvious outbreaks, reports of RT 017 in
Europe were scarce. During the late 1990s, the preva-
lence of RT 017 was 2.5% (9/364) in France [67].
During 2008–2009, RT 017 was responsible for 4.9%
(2/41) of severe CDI cases in Germany [84]. In 2012,
only one out of 171 (0.6%) C. diﬃcile isolates from
Austria was classiﬁed as C. diﬃcile RT 017 [68]. A
pan-European study reported an overall prevalence of
Figure 5. Timeline of C. diﬃcile RT 017 reports around the world. Outbreaks refer to an increase in the regional prevalence of RT
017, which is conﬁrmed either to be clonal or with evidence suggesting that isolates came from the same source. Endemic presence
refers to prevalence reports that were not associated with outbreaks.
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C. diﬃcile RT 017 during 2011–2014 of 1.8% (16/866)
[85]. Portugal was the only European country to report
a prevalence of C. diﬃcile RT 017 higher than 10% [97].
Australia
Several epidemiological studies conducted in various
regions of Australia with C. diﬃcile RT 017 being
found at a much lower prevalence compared to Asia.
The prevalence of C. diﬃcile RT 017 infection was ca.
3% [78–81] suggesting that those cases are are more
likely to be imported rather than caused by endemic
strains.
Africa
The number of studies on CDI in Africa is very lim-
ited. To date, the only country with reported
C. diﬃcile RT 017 infection is South Africa, where a
very high prevalence of RT 017 among diarrhoeal
patients in tuberculosis hospitals was seen
[77,98,99]. Historically, Cape Town in South Africa
has been an important port city where ships coming
from and going to Asia, Australia and Europe
stopped during their voyages. The introduction of
C. diﬃcile RT 017 may merely reﬂect travel between
these regions, however, it appears that C. diﬃcile
RT 017 has now become established within the hos-
pital system in South Africa. Patients testing positive
for C. diﬃcile are at high risk of mortality, and tuber-
culosis is an additional risk factor for CDI in popu-
lations with HIV [100].
C. diﬃcile RT 017 in animals
Recently, many C. diﬃcile strains associated with CDI
in humans have also been isolated from animals or ani-
mal products suggesting that CDI may be transmitted
from animals [101]. Despite its high prevalence in
the Asian human population [102], there have never
been any reports of C. diﬃcile RT 017 in animals in
this region [103,104], and it has rarely been reported
in animals elsewhere. C. diﬃcile RT 017 has been iso-
lated from calves in Canada [105] and rabbits in Italy
[106]. The WGS study undertaken in the United King-
dom by Cairns et al. involving 277 C. diﬃcile RT 017
strains only included 24 strains of animal origin [33].
The reasons why RT 017 is apparently not prevalent
in animals have not been elucidated.
Role of antimicrobial resistance in the
outbreaks of C. diﬃcile RT 017
AMR plays an important role in the dissemination of
many C. diﬃcile RTs. Being resistant to antimicrobials
while the intestinal microbiota is disrupted allows
C. diﬃcile to survive, produce toxins and eventually
cause disease [2]. Furthermore, being intrinsically
resistant to alcohol and desiccation, C. diﬃcile as a
spore can survive within the hospital environment
and spread to patients. Antimicrobial resistance has
been associated with CDI outbreaks in the past; in par-
ticular, the outbreaks of “epidemic” C. diﬃcile RT 027
in North America and Europe were associated with
ﬂuoroquinolone and rifampicin resistance.
Outbreaks of infection with C. diﬃcile RT 017 have
been linked with clindamycin- and ﬂuoroquinolone-
resistant strains [13,16,18,21]. Besides these antimi-
crobials, C. diﬃcile RT 017 also has higher rates of
resistance to tetracyclines and rifaximin [107–109].
Tetracycline resistance was associated with an out-
break of C. diﬃcile RT 078 [110,111]. Rifaximin is a
derivative of rifampicin which was also associated
with the outbreak of C. diﬃcile RT 027 [112,113].
There is no doubt that misuse of these antimicrobials
may lead to the future outbreaks of C. diﬃcile RT
017, given that it is endemic in East and South East
Asia, where tetracycline and rifampicin are commonly
prescribed for many tropical infections and tubercu-
losis, respectively.
Conclusions
C. diﬃcile RT 017 is one of the most successful RTs of
C. diﬃcile in the world. It was the ﬁrst A-B+ C. diﬃcile
shown to cause CDI following several outbreaks. This
discovery led to a better understanding of the patho-
genesis of CDI in general, together with the roles of
TcdA and TcdB, and eventually lead to changes in
the way the laboratory diagnosis of CDI was made.
The high rate of resistance to many antimicrobial
agents provides hints as to how C. diﬃcile RT 017
spread throughout the globe. It also gives us a warning
that antimicrobial stewardship is needed to prevent
further outbreaks.
The ancestral home of C. diﬃcile RT 017 remains
controversial, however, the weight of epidemiological
evidence suggests that this strain originated in Asia
and spread to other regions of the world long before
the much-publicised spread of RT 027. Particular clini-
cal characteristics of C. diﬃcile RT 017 infection have
yet to be determined. Why C. diﬃcile RT 017 is not
found more commonly in animals despite successful
human spread also remains unclear, however, this
may just reﬂect a lack of animal studies in Asia. Also,
there has been no study comparing phenotypic charac-
teristics of C. diﬃcile RT 017, such as sporulation, ger-
mination and motility, with other epidemic strains.
Since these properties are related to the spread of
C. diﬃcile, such studies may uncover important factors
that help in the control of C. diﬃcile RT 017 spread and
prevent further outbreaks.
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